Bayer Schering Pharma acquires preclinical anticancer programme from Nycomed

Published: 7-Aug-2008
Sustainability Research & Development

Bayer Schering Pharma is expanding its oncology pipeline with the acquisition of a preclinical oncology programme from Swiss pharma company Nycomed.


Bayer Schering Pharma is expanding its oncology pipeline with the acquisition of a preclinical oncology programme from Swiss pharma company Nycomed.

The agreement comprises two potential drug candidates and an extensive set of back-up compounds targeting a kinase critical for growth and survival of cancer cells.

Bayer Schering Pharma is making this investment following Nycomed's strategic decision not to invest further in oncology r&d activities and will assume full development and commercialization rights of the programme.

Nycomed will receive an initial reward and payments upon completion of agreed preclinical and regulatory milestones. Overall payments could total Euro 52m.

"The acquisition of this promising programme strengthens Bayer Schering Pharma's oncology pipeline as it is complementary to existing in-house approaches," says Professor. Andreas Busch, member of the board of management of Bayer Schering Pharma, responsible for global drug discovery. "The deal underpins our commitment to oncology research and our long-term aspiration to provide new treatment options for patients suffering from cancer."

See more

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Read more
Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP
Research & Development

LIfT BioSciences licenses Bayer's Cambridge lab facilities to advance oncology research

LIfT will use Bayer's Co.Lab facilities to advance its immuno-modulatory alpha neutrophil platform for the mitigation of treatment resistance in solid tumours
Research & Development

Nanoform and Takeda team up to advance plasma-derived therapy development

The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective
Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Subscribe now